I store placebo- kontrollerede og i langtids kliniske forsøg, udviklede mellem 40 og 50% af patienterne vedvarende asymptomatisk lymfocytose, mens de var i behandling med Raptiva.
Leucocytosis and lymphocytosis: in large placebo-controlled and in long-term clinical studies, between 40 and 50% of patients developed sustained asymptomatic lymphocytosis during Raptiva therapy.